Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 5/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SMO | Q99835 | 3/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | ACR | P10323 | 1/20 | 0.44 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4627551 | 0.87 | POLB (0.59) | SCN2ASCN5AHPGDSMN1; SMN2PRSS1 | |
| SCHEMBL4629431 | 0.84 | SCN2A (0.70) | SCN2ASCN5AHPGDSMN1; SMN2SMO | |
| SCHEMBL4629231 | 0.83 | SCN2A (0.69) | SCN2ASCN5AHPGDSMN1; SMN2PRSS1 | |
| SCHEMBL4629416 | 0.81 | ALDH1A1 (0.47) | SCN2ASCN5AHPGDSMN1; SMN2SMO | |
| SCHEMBL4628531 | 0.74 | RAB9A (0.56) | SCN2ASCN5AHPGDSMN1; SMN2NPC1 | |
| SCHEMBL4628715 | 0.74 | SCN2A (0.72) | SCN2ASCN5ASMN1; SMN2POLBNPC1 | |
| SCHEMBL14095973 | 0.73 | SIRT1 (0.59) | HPGDSMN1; SMN2NPC1ALDH1A1RAB9A | |
| SCHEMBL4628463 | 0.73 | NPC1 (0.55) | SMN1; SMN2BCAT2EPHX2NR1H4NPC1 | |
| SCHEMBL15328038 | 0.71 | BCAT2 (0.65) | SCN2ASCN5AHPGDPOLBBCAT2 | |
| SCHEMBL4628494 | 0.71 | SCN2A (0.80) | SCN2ASCN5ASMN1; SMN2PRSS1ACR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | claimed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | claimed |
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1032556-A4 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1032556-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999020599-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | SCN2A 1613/4885SCN5A 1196/4885HPGD 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.